Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.76 |
| ▸ | MAP3K7 | O43318 | 4/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | ROS1 | P08922 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16207132 | 0.92 | EGFR (0.83) | EGFRMAP3K7MAP2K1FLT3EML4 | |
| SCHEMBL16207039 | 0.91 | EGFR (0.78) | EGFRMAP3K7MAP2K1MAPK1FLT3 | |
| SCHEMBL16207032 | 0.89 | EGFR (0.85) | EGFRMAP3K7MAP2K1MAPK1FLT3 | |
| SCHEMBL16207123 | 0.89 | EGFR (0.84) | EGFRMAP3K7FLT3EML4ALK | |
| SCHEMBL16207000 | 0.89 | EGFR (0.87) | EGFRMAP3K7MAP2K1MAPK1FLT3 | |
| SCHEMBL16206913 | 0.87 | EGFR (0.64) | EGFRFLT3EML4ALKRET | |
| SCHEMBL16195490 | 0.87 | EGFR (1.00) | EGFRMAP3K7MAP2K1MAPK1FLT3 | |
| SCHEMBL16206994 | 0.86 | EGFR (0.84) | EGFRMAP3K7MAP2K1MAPK1FLT3 | |
| SCHEMBL16207128 | 0.86 | EGFR (0.84) | EGFRMAP3K7MAP2K1MAPK1FLT3 | |
| SCHEMBL16207129 | 0.86 | EGFR (0.77) | EGFRMAP3K7MAP2K1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | EGFR 1/4885MAP3K7 269/4885MAP2K1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.